|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIGQ |
Gene summary for PIGQ |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIGQ | Gene ID | 9091 |
| Gene name | phosphatidylinositol glycan anchor biosynthesis class Q | |
| Gene Alias | DEE77 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | B2RAU6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9091 | PIGQ | LZE7T | Human | Esophagus | ESCC | 2.69e-02 | 1.25e-01 | 0.0667 |
| 9091 | PIGQ | LZE22T | Human | Esophagus | ESCC | 8.31e-04 | 3.02e-01 | 0.068 |
| 9091 | PIGQ | LZE24T | Human | Esophagus | ESCC | 2.80e-18 | 4.05e-01 | 0.0596 |
| 9091 | PIGQ | P1T-E | Human | Esophagus | ESCC | 4.94e-05 | 2.80e-01 | 0.0875 |
| 9091 | PIGQ | P2T-E | Human | Esophagus | ESCC | 8.42e-25 | 4.69e-01 | 0.1177 |
| 9091 | PIGQ | P4T-E | Human | Esophagus | ESCC | 4.41e-09 | 2.08e-01 | 0.1323 |
| 9091 | PIGQ | P5T-E | Human | Esophagus | ESCC | 3.28e-08 | 1.23e-01 | 0.1327 |
| 9091 | PIGQ | P8T-E | Human | Esophagus | ESCC | 1.64e-18 | 2.38e-01 | 0.0889 |
| 9091 | PIGQ | P10T-E | Human | Esophagus | ESCC | 2.49e-06 | 4.69e-02 | 0.116 |
| 9091 | PIGQ | P11T-E | Human | Esophagus | ESCC | 1.13e-12 | 4.81e-01 | 0.1426 |
| 9091 | PIGQ | P12T-E | Human | Esophagus | ESCC | 1.78e-18 | 2.90e-01 | 0.1122 |
| 9091 | PIGQ | P15T-E | Human | Esophagus | ESCC | 6.70e-16 | 3.23e-01 | 0.1149 |
| 9091 | PIGQ | P16T-E | Human | Esophagus | ESCC | 6.61e-13 | 1.75e-01 | 0.1153 |
| 9091 | PIGQ | P17T-E | Human | Esophagus | ESCC | 8.28e-06 | 2.36e-01 | 0.1278 |
| 9091 | PIGQ | P19T-E | Human | Esophagus | ESCC | 1.35e-07 | 5.90e-01 | 0.1662 |
| 9091 | PIGQ | P20T-E | Human | Esophagus | ESCC | 2.99e-09 | 2.29e-01 | 0.1124 |
| 9091 | PIGQ | P21T-E | Human | Esophagus | ESCC | 5.01e-22 | 4.12e-01 | 0.1617 |
| 9091 | PIGQ | P22T-E | Human | Esophagus | ESCC | 2.56e-15 | 2.73e-01 | 0.1236 |
| 9091 | PIGQ | P23T-E | Human | Esophagus | ESCC | 1.93e-16 | 3.55e-01 | 0.108 |
| 9091 | PIGQ | P24T-E | Human | Esophagus | ESCC | 7.33e-15 | 2.33e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
| GO:00421573 | Esophagus | ESCC | lipoprotein metabolic process | 86/8552 | 135/18723 | 1.78e-05 | 1.57e-04 | 86 |
| GO:00064973 | Esophagus | ESCC | protein lipidation | 62/8552 | 92/18723 | 2.08e-05 | 1.80e-04 | 62 |
| GO:00421583 | Esophagus | ESCC | lipoprotein biosynthetic process | 64/8552 | 96/18723 | 2.61e-05 | 2.20e-04 | 64 |
| GO:00065063 | Esophagus | ESCC | GPI anchor biosynthetic process | 26/8552 | 32/18723 | 3.97e-05 | 3.21e-04 | 26 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:00065053 | Esophagus | ESCC | GPI anchor metabolic process | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| GO:00066642 | Esophagus | ESCC | glycolipid metabolic process | 63/8552 | 100/18723 | 3.55e-04 | 2.06e-03 | 63 |
| GO:19035092 | Esophagus | ESCC | liposaccharide metabolic process | 63/8552 | 101/18723 | 5.25e-04 | 2.90e-03 | 63 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:0009247 | Esophagus | ESCC | glycolipid biosynthetic process | 42/8552 | 68/18723 | 5.48e-03 | 2.05e-02 | 42 |
| GO:00066611 | Esophagus | ESCC | phosphatidylinositol biosynthetic process | 73/8552 | 131/18723 | 1.31e-02 | 4.28e-02 | 73 |
| GO:0042157 | Liver | Cirrhotic | lipoprotein metabolic process | 53/4634 | 135/18723 | 1.32e-04 | 1.29e-03 | 53 |
| GO:0006643 | Liver | Cirrhotic | membrane lipid metabolic process | 69/4634 | 203/18723 | 1.89e-03 | 1.19e-02 | 69 |
| GO:0042158 | Liver | Cirrhotic | lipoprotein biosynthetic process | 36/4634 | 96/18723 | 3.69e-03 | 2.03e-02 | 36 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005632 | Esophagus | ESCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 21/4205 | 26/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 21 |
| hsa0056311 | Esophagus | ESCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 21/4205 | 26/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 21 |
| hsa00563 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| hsa005631 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIGQ | SNV | Missense_Mutation | novel | c.803N>C | p.Asn268Thr | p.N268T | Q9BRB3 | protein_coding | tolerated(0.17) | benign(0.015) | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PIGQ | SNV | Missense_Mutation | rs552478942 | c.103N>T | p.Val35Phe | p.V35F | Q9BRB3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.942) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| PIGQ | SNV | Missense_Mutation | c.1468N>A | p.Leu490Ile | p.L490I | Q9BRB3 | protein_coding | tolerated(0.16) | benign(0.076) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PIGQ | SNV | Missense_Mutation | c.768N>A | p.His256Gln | p.H256Q | Q9BRB3 | protein_coding | tolerated(0.18) | benign(0.021) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PIGQ | SNV | Missense_Mutation | rs552478942 | c.103G>T | p.Val35Phe | p.V35F | Q9BRB3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.942) | TCGA-B6-A0RQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PIGQ | SNV | Missense_Mutation | rs552478942 | c.103N>T | p.Val35Phe | p.V35F | Q9BRB3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.942) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| PIGQ | SNV | Missense_Mutation | rs552478942 | c.103N>T | p.Val35Phe | p.V35F | Q9BRB3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.942) | TCGA-C8-A138-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PIGQ | SNV | Missense_Mutation | rs552478942 | c.103N>T | p.Val35Phe | p.V35F | Q9BRB3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.942) | TCGA-D8-A145-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| PIGQ | SNV | Missense_Mutation | rs148273392 | c.91N>A | p.Val31Met | p.V31M | Q9BRB3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.982) | TCGA-E9-A1RB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate | SD |
| PIGQ | deletion | In_Frame_Del | novel | c.829_840delAACACGGTGGCC | p.Asn277_Ala280del | p.N277_A280del | Q9BRB3 | protein_coding | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |